Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAM for Small Joint Arthritis of the Hand
NCT05747469Phase 1Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Aug 2023
- Primary completion
- Jan 2027
- Modality
- Tissue Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Renuva Allograft Adipose Matrix in osteoarthritis (OA), sponsored by Cedars-Sinai Medical Center. Primary endpoints: Range of Motion at 12 months, Strength Measures at 12 months and 3 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
Renuva Allograft Adipose Matrix
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05747469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747469.